Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
- Written by ACN Newswire - Press Releases
.
Is your search bar your competitor’s best salesperson?
A few weeks ago, I was watching the Super Bowl. Traditionally, those halftime ad spots are reserved for the world’s biggest, most established bran...
AIIMS Group and AdVisible merge
Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience ...
Block's layoffs are a design win. Here's why
We spend millions designing features that save users 30 seconds. Block just saved thousands of employees 40 hours a week. That's not a crisis. That's...
Why I Decided to Build a Better Way to Build Homes
Why does building a home still feel like stepping into the unknown? In an industry where costs blow out and decisions come too late, certainty has...
Leonardo.Ai reveals new brand, expanding its creator-first platform for the next era of generative AI
The company has also launched its developer API to empower creators and builders to integrate AI into their workflows SYDNEY, Australia – 19 Febr...
Psychosocial injury risk starts inside workplace microcultures
Psychological injury is now one of the most expensive categories of workers compensation claims in Australia, with Safe Work Australia reporting t...